Opthea (ASX: OPT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Opthea Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Opthea (ASX: OPT)
Latest News
Share Gainers
Opthea share price rockets 9% higher on bullish broker note
Growth Shares
3 ASX growth shares heading for a $1 billion market cap
Growth Shares
My October favourites: 3 ASX shares for the long-term
Share Gainers
Why the Opthea share price has rocketed 450% higher this year
Healthcare Shares
3 ASX growth shares in the healthcare sector to watch
ASX Share Market News
Why the Polynovo share price is now up 24x in 5 years
ASX Share Market News
The Orthocell share price is going nuts on claims of a blockbuster medical breakthrough
ASX Share Market News
Mesoblast shares halted as it asks investors to tip in another $75 million
ASX Share Market News
Paradigm reports "ground-breaking" osteoarthritis discovery: Is it the real deal?
ASX Share Market News
These are the 10 hottest small-cap shares over the past year
Share Fallers
Why Afterpay, OceanaGold, Opthea, & Syrah shares tumbled lower today
ASX Share Market News
Opthea share price lifts on clinical trial update: Is it a spec buy?
Frequently Asked Questions
-
No, Opthea does not pay shareholder dividends at this time.
-
Opthea Limited listed on the ASX on 18 April 1991.
OPT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Opthea
Opthea Limited (ASX: OPT) is a clinical-stage biopharmaceutical company. Following the failure of its Phase 3 wet age-related macular degeneration (AMD) trials, the company discontinued that program and relaunched in June 2026 with a new focus on OPT-302 as a potential treatment for lymphangioleiomyomatosis (LAM), a rare lung disease.
Shareholders have been asked to approve a proposed name change to Ceryvyn Therapeutics to reflect the new direction.
OPT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 08 Jul 2026 | $0.01 | $0.00 | 0.00% | 7,777,329 | $0.01 | $0.02 | $0.01 |
| 07 Jul 2026 | $0.01 | $0.00 | 0.00% | 4,723,387 | $0.02 | $0.02 | $0.01 |
| 06 Jul 2026 | $0.02 | $0.00 | 0.00% | 9,873,809 | $0.02 | $0.02 | $0.01 |
| 03 Jul 2026 | $0.01 | $0.00 | 0.00% | 3,708,050 | $0.02 | $0.02 | $0.01 |
| 02 Jul 2026 | $0.02 | $0.00 | 0.00% | 19,796,064 | $0.02 | $0.02 | $0.01 |
